Variation in preoperative antithrombotic strategy, severe bleeding and use of blood products in coronary artery bypass grafting. Results from the multicenter E-CABG registry

2018

EUROPEAN HEART JOURNAL. QUALITY OF CARE & CLINICAL OUTCOMES

Variation in preoperative antithrombotic strategy, severe bleeding and use of blood products in coronary artery bypass grafting. Results from the multicenter E-CABG registry

01 Pubblicazione su rivista

Biancari Fausto, Mariscalco Giovanni, Gherli Riccardo, Reichart Daniel, Onorati Francesco, Faggian Giuseppe, Franzese Ilaria, Santarpino Giuseppe, Fischlein Theodor, Rubino Antonino S, Maselli Daniele, Nardella Saverio, Salsano Antonio, Nicolini Francesco, Zanobini Marco, Saccocci Matteo, Ruggieri Vito G, Bounader Karl, Perrotti Andrea, Rosato Stefano, D'Errigo Paola, D'Andrea Vito, De Feo Marisa, Tauriainen Tuomas, Gatti Giuseppe, Dalén Magnus

DOI: 10.1093/ehjqcco/qcy027

ISSN: 2058-5225

Background:

No data exists on inter-institutional differences in terms of adherence to international guidelines regarding the discontinuation of antithrombotics and rates of severe bleeding in coronary artery bypass grafting (CABG).
Methods and Results:

This is an analysis of 7118 patients from the prospective multicenter E-CABG registry who underwent isolated CABG in 15 European centers. Preoperative pause of P2Y12 receptor antagonists shorter than that suggested by the 2017 ESC guidelines (overall, 11.6%) ranged from 0.7% to 24.8% between centers (adjusted p Conclusions:

Adherence to the current guidelines on the early discontinuation of P2Y12 receptor antagonists is of utmost importance to reduce excessive bleeding and early mortality after CABG. Inter-institutional variation should be considered for a correct interpretation of the results in multicentre studies evaluating perioperative bleeding and use of blood products.

antithrombotic bleeding blood transfusion. Downloaded P2Y12